Ray Dalio I Mab Transaction History

Bridgewater Associates, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$3.08 - $7.39 $167,006 - $400,707	-54,223 Reduced 26.35%	151,560 $524,000
Q4 2022 Feb 13, 2023	SELL	$3.22 - $4.86 $24,546 - $37,047	-7,623 Reduced 3.57%	205,783 $860,000
Q3 2022 Nov 10, 2022	SELL	$4.01 - $12.34 $144,829 - $445,683	-36,117 Reduced 14.47%	213,406 $856,000
Q2 2022 Aug 11, 2022	SELL	$8.27 - $18.43 $516,668 - $1.15 Million	-62,475 Reduced 20.02%	249,523 $2.82 Million
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $1.58 Million - $5.93 Million	126,384 Added 68.09%	311,998 $5.07 Million

Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $1.79 Million - $2.95 Million	39,630 Added 27.15%	185,614 $8.8 Million
Q3 2021 Nov 12, 2021	BUY	$57.18 - $84.43 $6.45 Million - $9.52 Million	112,730 Added 339.0%	145,984 $10.6 Million
Q2 2021 Aug 13, 2021	BUY	$47.86 - $83.95 $1.59 Million - $2.79 Million	33,254 New	33,254 $2.79 Million

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.